Phase III Randomized Controlled Trial of Pembrolizumab with Platinum-Based Chemotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment of NSCLC with PD-L1 ≥50%

The primary objective of this study is to evaluate the efficacy of a **pembrolizumab** and platinum-based chemotherapy combination compared to pembrolizumab monotherapy in the first-line treatment of patients with **non-small-cell lung cancer** (NSCLC) exhibiting PD-L1 expression ≥50% on tumor cells. This comparison is clinically relevant as it aims to determine the most effective treatment strategy for improving patient outcomes in this specific subset of NSCLC, potentially influencing future therapeutic guidelines and decision-making processes in oncology.

The clinical trial focuses on participants diagnosed with **non-small-cell lung cancer**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The sponsor has not disclosed key inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, open-label, controlled phase III study. It aims to compare the efficacy of a pembrolizumab and platinum-based chemotherapy combination with pembrolizumab monotherapy in the first-line treatment of patients with **non-small-cell lung cancer** (NSCLC) exhibiting PD-L1 expression of 50% or greater on tumor cells. The trial is expected to commence recruitment on December 22, 2020, and is projected to conclude by December 21, 2025. Participants will be randomly assigned to one of the two treatment arms, ensuring an unbiased distribution of patient characteristics across the study groups.

The trial will involve a series of structured study visits. Initially, an inclusion visit will be conducted to screen potential participants for eligibility based on predefined criteria. Following successful enrollment, participants will undergo regular follow-up visits to monitor treatment response, assess safety, and collect data on any adverse events. These visits will be scheduled at intervals deemed appropriate by the study protocol to ensure comprehensive data collection and participant safety. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

Participant involvement in the trial is expected to last until the study's completion, unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise participant safety or data integrity. The trial's design and procedures are meticulously structured to ensure the collection of robust and reliable data, contributing to the understanding of treatment efficacy and safety in the specified patient population.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized under phase 5, indicating a focus on post-marketing surveillance to gather additional information on the drug's effectiveness and safety. The estimated recruitment start date was December 22, 2020, with an anticipated end date of December 21, 2025. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to evaluate the treatment's impact. The trial phase suggests that efficacy assessments may include real-world data collection and long-term outcome measures. The absence of detailed endpoints implies that the trial may utilize a variety of methods to assess efficacy, potentially including patient-reported outcomes, clinical assessments, or other relevant measures as determined by the study protocol.